Neuroreceptor imaging: New developments in PET and SPECT imaging of neuroreceptor binding (including dopamine transporters, vesicle transporters and post synaptic receptor sites)

Current Opinion in Neurology

Volumn 11, Issue 4, 1998, Pages 327-333

  Stoessl, A Jon ^a   Ruth, Thomas J ^b  

^a TRIUMF   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; LEVODOPA; POSTSYNAPTIC RECEPTOR; RACLOPRIDE; TRACER;

DYSTONIA; GILLES DE LA TOURETTE SYNDROME; HUMAN; HUNTINGTON CHOREA; INTRAVENOUS DRUG ADMINISTRATION; MOTOR DYSFUNCTION; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; RECEPTOR BINDING; RECEPTOR DENSITY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

BIOLOGICAL TRANSPORT; CARRIER PROTEINS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; NEUROPEPTIDES; RECEPTORS, DOPAMINE; RECEPTORS, SENSORY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VESICULAR BIOGENIC AMINE TRANSPORT PROTEINS;

EID: 7344238534     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199808000-00008     Document Type: Review

References (77)

1. 18F-fallypride in nonhuman primates using positron emission tomography. Synapse 1997; 27:1-13.
2. 18F](N-methyl)benperidol: a novel PET tracer for assessment of dopaminergic D2-like receptor binding. J Cereb Blood Flow Metab 1997; 17:833-845.
3. 123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. Synapse 1997; 27:183-190.
4. Emond P, Chalon S, Garreau L, Dognon AM, Bodard S, Frangin Y, et al. A new iodinated tropane derivative (β-CDIT) for in vivo dopamine transporter exploration: comparison with β-CIT. Synapse 1997; 26:72-80.
5. Emond P, Garreau L, Chalon S, Boazi M, Caillet M, Bricard J, et al. Synthesis and ligand binding of nortropane derivatives: N-substituted 2β-carbomethoxy-3β-(4′-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2β-carbomethoxy-Sβ-(3′,4′- disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter. J Med Chem 1997; 40:1366-1372.
6. 125I]β-CIT for dopamine transporter visualization: autoradiographic evaluation in the human brain. Nucl Med Biol 1997;24:629-634.
7. 11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology 1997; 48:1578-1583.
8. 11C]β-CIT-FP for quantitation of the dopamine transporter. Nucl Med Biol 1997; 24:621-627.
9. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, et al. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 1997; 94:2569-2574. The method presented in this paper provides an indirect measure of the in-vivo synaptic dopamine concentration, which should have wide application in monitoring different stages of disease as well as response to therapies.
10. Booij J, Korn P, Linszen DH, van Royen EA. Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med 1997; 24:674-677.
11. Laruelle M, Iyer RN, al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, et al. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 1997; 25:1-14. This paper shows that SPECT can be used to measure intrasynaptic dopamine release in vivo.
12. Laruelle M, D'Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL, et al. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 1997; 17:162-174.
13. 11C]raclopride displacement and PET. Neurology 1996; 46:1430-1436.
14. 11C-raclo-pride PET. Synapse 1998; 28:66-70. This paper demonstrates the measures of D2 concentration with raclopride are stable over a period of up to 1 year.
15. 11C]raclopride: combined PET microdialysis studies. J Cereb Blood Flow Metab 1997; 17:932-942.
16. 11C]raclopride binding with continuous infusion. J Cereb Blood Flow Metab 1997; 17:437-447.
17. 11C]dihydrotetrabenazine (DTBZ) and positron emission tomography. J Cereb Blood Flow Metab 1997; 17:919-931.
18. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in Parkinsonism - a prospective study. Can J Neurol Sci 1991; 18:275-278.
19. 18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol 1993; 34:324-330.
20. Pate BD, Kawamata T, Yamada T, McGeer EG, Hewitt KA, Snow BJ, et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann Neurol 1993; 34:331-338.
21. 123I]β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996; 46:231-237.
22. 123I]β-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997; 50:9-24.
23. 123I]β-CIT SPECT visualizes dopamine transporter loss in de novo parkinsonian patients. Eur Neurol 1998; 39:44-48.
24. 123]β-CIT SPECT. J Neurol 1998; 245:14-20.
25. Seibyl JP, Marek K, Sheff K, Baldwin RM, Zoghbi S, Zea-Ponce Y, et al. Test/retest reproducibility of iodine-123-β-CIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J Nucl Med 1997; 38:1453-1459.
26. Kim HJ, Im JH, Yang SO, Moon DH, Ryu JS, Bong JK, et al. Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects. J Nucl Med 1997; 38:1703-1711.
27. 123I]IPT and single-photon emission tomography. Eur J Nucl Med 1997; 24:415-421.
28. 123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med 1997; 24:68-71.
29. 123-β-CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med 1996; 37:1760-1765.
30. Vanderborght T, Kilbourn M, Desmond T, Kuhl D, Frey K. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur J Pharmacol 1995; 294:577-583.
31. Wilson JM, Kish SJ. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci 1996; 16:3507-3510.
32. Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, Kuhl DE. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann Neurol 1996; 40:873-884.
33. Kilbourn MR. In vivo radiotracers for vesicular neurotransmitter transporters. Nucl Med Biol 1997; 24:615-619. This is a thorough review of vesicular neurotransmitter transporters that reflects primarily the author's extensive work.
34. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's Disease. N Engl J Med 1988; 318:876-880.
35. Lee CS, Samimi A, Schulzer M, Sossi V, Dobko TJ, Chan GLY, et al. Heterogeneous severity of lesions in the striatum of patients with Parkinson's disease: in vivo PET studies using dihydrotetrabenazine, methylphenidate and F-DOPA [abstract]. Neurology 1998; 50 (Suppl 4):A391-A392.
36. 11C-raclopride and positron emission tomography. Ann Neurol 1992; 31:184-192.
37. 11C]raclopride. Mov Disord 1997; 12:33-38.
38. Hertel A, Weppner M, Baas H, Schreiner M, Maul FD, Baum RP, et al. Quantitation of IBZM dopamine receptor SPET in de novo Parkinson patients before and during therapy. Nucl Med Commun 1997; 18:811-822.
39. 123I-IBZM binding compared with long-term clinical follow-up in patients with de novo parkinsonism. Mov Disord 1998: 13:16-19.
40. Pirker W, Asenbaum S, Wenger S, Komhuber J, Angelberger P, Deecke L, et al. Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease. J Nucl Med 1997; 38:1711-1717.
41. 11C-raclopride PET findings in patients with parkinsonism. Nucl Med Commun 1994; 15:806-813.
42. Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 1997; 49:717-723.
43. Kishore A, De La Fuente-Fernandez R, Snow BJ, Schulzer M, Mak E, Huser J, et al. Levodopa-induced dyskinesias in idiopalhic parkinsonism (IP): a simultaneous PET study of dopamine D1 and D2 receptors [abstract]. Neurology 1997; 48 (Suppl 3):A327.
44. 11C-raclopride is altered by drugs that modify synaptic dopamine levels. Synapse 1993; 13:350-356.
45. 3H raclopride: implications for positron emission tomography of the human brain. Synapse 1989; 3:96-97.
46. 123I-iomazenil SPECT. Nippon Rinsho 1997; 55:244-248.
47. Piccini P, Weeks RA, Brooks DJ. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 1997; 42:720-726.
48. Engber TM, Susel Z, Kuo S, Gerfen CR, Chase TN. Levodopareplacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats. Brain Res 1991; 552:113-118.
49. Newman DD, Rajakumar N, Flumerfelt BA, Stoessl AJ. A kappa opioid antagonist blocks sensitization in a rodent model of Parkinson's disease. NeuroReport 1997; 8:669-672.
50. Brooks DJ, Salmon EP, Mathias CJ, Quinn N, Leenders KL, Bannister R, et al. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain 1990; 113:1539-1552.
51. Antonini A, Leenders KL, Vontobel P, Maguire RP, Missimer J, Psylla M, Gunther I. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997; 120:2187-2195.
52. Gilman S, Frey KA, Koeppe RA, Junck L, Little R, Vander Borght TM, et al. Decreased striatal monoaminergic terminals in olivopontocerebellar atrophy and multiple system atrophy demonstrated with positron emission tomography. Ann Neurol 1996; 40:885-892.
53. 123I-β-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 1997; 24:320-325.
54. Shinotoh H, Thiessen B, Snow BJ, Hashimoto S, MacLeod P, Silveira I, et al. Fluorodopa and raclopride PET analysis of patients with Machado-Joseph disease. Neurology 1997; 49:1133-1136.
55. Shinotoh H, Snow BJ, Chu NS, Huang CC, Lu CS, Lee C, et al. Presynaptic and postsynaptic striatal dopaminergic function in patients with manganese intoxication: a positron emission tomography study. Neurology 1997; 48:1053-1056.
56. Sedvall G, Karlsson P, Lundin A, Anvret M, Suhara T, Halldin C, Farde L. Dopamine D1 receptor number - a sensitive PET marker for early brain degeneration in Huntington's disease. Eur Arch Psychiatry Clin Neurosci 1994; 243:249-255.
57. Ginovart N, Lundin A, Farde L, Halldin C, Backman L, Swahn CG, et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 1997; 120:503-514.
58. 11C-diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping. J Cereb Blood Flow Metat 1997; 17:943-949.
59. Holthoff VA, Koeppe RA, Frey KA, Penney JB, Markel DS, Kuhl DE, Young AB. Positron emission tomography measures of benzodiazepine receptors in Huntington's disease. Ann Neurol 1993; 34:76-81.
60. Weeks RA, Piccini P, Harding AE, Brooks DJ. Striatal D1 and D2dopamine receptor loss in asymptomatic mutation carriers of Huntington'sdisease. Ann Neurol 1996; 40:49-54.
61. 11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol 1998; 43:253-255.
62. Stoessl AJ, Martin WRW, Hayden MR, Adam MJ, Ruth TJ, Rajput A, et al. Dopamine in Huntington disease - studies using positron emission tomography. Neurology 1986; 36 (Suppl 1):310.
63. Backman L, Robins-Wahlin TB, Lundin A, Ginovart N, Farde L. Cognitive deficits in Huntington's disease are predicted by dopaminergic PET markers and brain volumes. Brain 1997; 120:2207-2217.
64. Singer HS, Hahn IH, Moran TH. Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndrome. Ann Neurol 1991; 30:558-562.
65. 123I]β-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am J Psychiatry 1995; 152:1359-1361.
66. George MS, Robertson MM, Costa DC, EII PJ, Trimble MR, Pilowski L, Verhoeff NP. Dopamine receptor availability in Tourette's syndrome. Psychiatry Res 1994; 55:193-203.
67. Turjanski N, Sawle GV, Playford ED, Weeks R, Lammertsma AA, Lees AJ, Brooks DJ. PET studies of the presynaptic and post synaptic dopaminergic system in Tourette's syndrome. J Neurol Neurosurg Psychiatry 1994; 57:688-692.
68. Wolf SS, Jones DW, Knable MB, Gorey JG, Lee KS, Hyde TM, et al. Tourette syndrome: prediction of phenotypic variation in monozygotic twins by caudate nucleus D2 receptor binding. Science 1996; 273:1225-1227.
69. Wong DF, Singer HS, Brandt J, Shaya E, Chen C, Brown J, et al. D2-like dopamine receptor density in Tourette syndrome measured by PET. J Nucl Med 1997; 38:1243-1247.
70. 18F]spiperone binding in putamen in idiopathic focal dystonia. J Neurosci 1997; 17:843-850.
71. 11C]-N-methyl-spiperone binding in patients with focal dystonia (torticollis) using positron emission tomography. J Neural Transm Park Dis Dement Sec 1993; 5:79-87.
72. 123]β-CIT. Mov Disord 1998; 13:319-323.
73. Ichinose H, Ohye T, Takahashi E, Seki N, Hori T, Segawa M, et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GPT cyclohydrolase I gene. Nature Genet 1994; 8:236-242.
74. Rajput AH, Gibb WR, Zhong XH, Shannak KS, Kish S, Chang LG, Hornykiewicz O. Dopa-responsive dystonia: pathological and biochemical observations in a case. Ann Neurol 1994; 35:396-402.
75. Snow BJ, Nygaard TG, Takahashi H, Calne DB. Positron emission tomographic studies of dopa-responsive dystonia and early-onset idiopathic parkinsonism. Ann Neurol 1993; 34:733-738.
76. 123I]β-CIT single-photon emission tomography in DOPA-responsive dystonia. Mov Disord 1997; 12:448-451.
77. 11C]raclopride and positron emission tomography. Neurology 1998; 50:1028-1032.